Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Instagram Outage Disrupts Thousands of U.S. Users 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
BOSTON, March 28, 2017 -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will present at the following investor conferences in April:
| 1st Annual H.C. Wainwright & Company NASH Investor Conference | |
| Location: St. Regis New York in New York City (Versailles Room) | |
| Presentation date / time: Monday, April 3, 2017, at 11:00 a.m. ET | |
| Presenter: Paresh N. Soni, MD, PhD, Chief Medical Officer | |
| 16th Annual Needham Healthcare Conference | |
| Location: Westin Grand Central Hotel in New York City | |
| Presentation date / time: Tuesday, April 4, 2017, at 3:00 p.m. ET | |
| Presenter: Ron Cooper, President and Chief Executive Officer | |
A live audio webcast of the Needham conference presentation will be accessible from the Investors page of Albireo’s website, ir.albireopharma.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will be available for replay on the Events & Presentations section of the Investors page of Albireo’s website for at least two weeks following the event.
About Albireo
Albireo is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo’s clinical pipeline includes two Phase 2 product candidates and one Phase 3 product candidate. Albireo was spun out from AstraZeneca in 2008.
Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.
Source: Albireo Pharma, Inc.
Investor Contact: Hans Vitzthum LifeSci Advisors, LLC. 212-915-2568 Media Contact: Heather Anderson 6 Degrees 980-938-0260 [email protected]
